Disposition and biotransformation of the antipsychotic agent olanzapine in humans

Kelem Kassahun, Edward Mattiuz, Eldon Nyhart, Boyd Obermeyer, Todd Gillespie, Anthony Murphy, R. Michael Goodwin, David Tupper, John Callaghan, Louis Lemberger

Research output: Contribution to journalArticle

191 Citations (Scopus)

Abstract

Disposition and biotransformation of the new antipsychotic agent olanzapine (OLZ) were studied in six male healthy volunteers after a single oral dose of 12.5 mg containing 100 μCi of [14C]OLZ. Biological fluids were analyzed for total radioactivity, the parent compound (GC/MS), and metabolites (electrospray LC/MB and LC/MS/MS). Mean radiocarbon recovery was ~87%, with 30% appearing in the faces and 57% excreted in the urine. Approximately half of the radiocarbon was excreted within 3 days, whereas >70% of the dose was recovered within 7 days of dosing. Circulating radioactivity was mostly restricted to the plasma compartment of blood. Mean peak plasma concentration of OLZ was 11 ng/ml, whereas that of radioactivity was 39 ng eq/ml. Mean plasma terminal elimination half-lives were 27 and 59 hr, respectively, for OLZ and total radioactivity. With the help of NMR and MS data, a major metabolite of OLZ in humans was characterized as a novel tertiary N-glucuronide in which the glucuronic acid moiety is attached to the nitrogen at position 10 of the benzodiazepine ring. Another N- glucuronide was detected in urine and identified as the quaternary N-linked 4'-N-glucuronide. Oxidative metabolism on the allylic methyl group resulted in 2-hydroxymethyl and 2-carboxylic acid derivatives of OLZ. The methyl piperazine moiety was also subject to oxidative attack, giving rise to the N-oxide and N-desmethyl metabolites. Other metabolites, including the N- desmethyl-2-carboxy derivative, resulted from metabolic reactions at both the 4' nitrogen and 2-methyl groups. The 10-N-glucuronide end OLZ were the two most abundant urinary components, accounting for ~13% and 7% of the dose, respectively. In fecal extracts, the only significant radioactive HPLC peaks were due to 10-N-glucuronide and OLZ representing, respectively, ~8% and 2% of the administered dose. Semiquantitative data obtained from plasma samples from subjects given [14C]OLZ suggest that the main circulating metabolite is 10-N-glucuronide. Thus, OLZ was extensively metabolized in humans via N-glucuronidation, allylic hydroxylation, N-oxidation, N- dealkylation and a combination thereof. The 10-N-glucuronidation pathway was the most important pathway both in terms of contribution to drug-related circulating species and as an excretory product in feces and urine.

Original languageEnglish (US)
Pages (from-to)81-93
Number of pages13
JournalDrug Metabolism and Disposition
Volume25
Issue number1
StatePublished - Jan 1997
Externally publishedYes

Fingerprint

olanzapine
Biotransformation
Antipsychotic Agents
Glucuronides
Metabolites
Radioactivity
Plasmas
Urine
Nitrogen
Dealkylation
Derivatives
Glucuronic Acid
Hydroxylation

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

Kassahun, K., Mattiuz, E., Nyhart, E., Obermeyer, B., Gillespie, T., Murphy, A., ... Lemberger, L. (1997). Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metabolism and Disposition, 25(1), 81-93.

Disposition and biotransformation of the antipsychotic agent olanzapine in humans. / Kassahun, Kelem; Mattiuz, Edward; Nyhart, Eldon; Obermeyer, Boyd; Gillespie, Todd; Murphy, Anthony; Goodwin, R. Michael; Tupper, David; Callaghan, John; Lemberger, Louis.

In: Drug Metabolism and Disposition, Vol. 25, No. 1, 01.1997, p. 81-93.

Research output: Contribution to journalArticle

Kassahun, K, Mattiuz, E, Nyhart, E, Obermeyer, B, Gillespie, T, Murphy, A, Goodwin, RM, Tupper, D, Callaghan, J & Lemberger, L 1997, 'Disposition and biotransformation of the antipsychotic agent olanzapine in humans', Drug Metabolism and Disposition, vol. 25, no. 1, pp. 81-93.
Kassahun K, Mattiuz E, Nyhart E, Obermeyer B, Gillespie T, Murphy A et al. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metabolism and Disposition. 1997 Jan;25(1):81-93.
Kassahun, Kelem ; Mattiuz, Edward ; Nyhart, Eldon ; Obermeyer, Boyd ; Gillespie, Todd ; Murphy, Anthony ; Goodwin, R. Michael ; Tupper, David ; Callaghan, John ; Lemberger, Louis. / Disposition and biotransformation of the antipsychotic agent olanzapine in humans. In: Drug Metabolism and Disposition. 1997 ; Vol. 25, No. 1. pp. 81-93.
@article{fbb4dee8fee94ef2a3ea47aa42a58994,
title = "Disposition and biotransformation of the antipsychotic agent olanzapine in humans",
abstract = "Disposition and biotransformation of the new antipsychotic agent olanzapine (OLZ) were studied in six male healthy volunteers after a single oral dose of 12.5 mg containing 100 μCi of [14C]OLZ. Biological fluids were analyzed for total radioactivity, the parent compound (GC/MS), and metabolites (electrospray LC/MB and LC/MS/MS). Mean radiocarbon recovery was ~87{\%}, with 30{\%} appearing in the faces and 57{\%} excreted in the urine. Approximately half of the radiocarbon was excreted within 3 days, whereas >70{\%} of the dose was recovered within 7 days of dosing. Circulating radioactivity was mostly restricted to the plasma compartment of blood. Mean peak plasma concentration of OLZ was 11 ng/ml, whereas that of radioactivity was 39 ng eq/ml. Mean plasma terminal elimination half-lives were 27 and 59 hr, respectively, for OLZ and total radioactivity. With the help of NMR and MS data, a major metabolite of OLZ in humans was characterized as a novel tertiary N-glucuronide in which the glucuronic acid moiety is attached to the nitrogen at position 10 of the benzodiazepine ring. Another N- glucuronide was detected in urine and identified as the quaternary N-linked 4'-N-glucuronide. Oxidative metabolism on the allylic methyl group resulted in 2-hydroxymethyl and 2-carboxylic acid derivatives of OLZ. The methyl piperazine moiety was also subject to oxidative attack, giving rise to the N-oxide and N-desmethyl metabolites. Other metabolites, including the N- desmethyl-2-carboxy derivative, resulted from metabolic reactions at both the 4' nitrogen and 2-methyl groups. The 10-N-glucuronide end OLZ were the two most abundant urinary components, accounting for ~13{\%} and 7{\%} of the dose, respectively. In fecal extracts, the only significant radioactive HPLC peaks were due to 10-N-glucuronide and OLZ representing, respectively, ~8{\%} and 2{\%} of the administered dose. Semiquantitative data obtained from plasma samples from subjects given [14C]OLZ suggest that the main circulating metabolite is 10-N-glucuronide. Thus, OLZ was extensively metabolized in humans via N-glucuronidation, allylic hydroxylation, N-oxidation, N- dealkylation and a combination thereof. The 10-N-glucuronidation pathway was the most important pathway both in terms of contribution to drug-related circulating species and as an excretory product in feces and urine.",
author = "Kelem Kassahun and Edward Mattiuz and Eldon Nyhart and Boyd Obermeyer and Todd Gillespie and Anthony Murphy and Goodwin, {R. Michael} and David Tupper and John Callaghan and Louis Lemberger",
year = "1997",
month = "1",
language = "English (US)",
volume = "25",
pages = "81--93",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Disposition and biotransformation of the antipsychotic agent olanzapine in humans

AU - Kassahun, Kelem

AU - Mattiuz, Edward

AU - Nyhart, Eldon

AU - Obermeyer, Boyd

AU - Gillespie, Todd

AU - Murphy, Anthony

AU - Goodwin, R. Michael

AU - Tupper, David

AU - Callaghan, John

AU - Lemberger, Louis

PY - 1997/1

Y1 - 1997/1

N2 - Disposition and biotransformation of the new antipsychotic agent olanzapine (OLZ) were studied in six male healthy volunteers after a single oral dose of 12.5 mg containing 100 μCi of [14C]OLZ. Biological fluids were analyzed for total radioactivity, the parent compound (GC/MS), and metabolites (electrospray LC/MB and LC/MS/MS). Mean radiocarbon recovery was ~87%, with 30% appearing in the faces and 57% excreted in the urine. Approximately half of the radiocarbon was excreted within 3 days, whereas >70% of the dose was recovered within 7 days of dosing. Circulating radioactivity was mostly restricted to the plasma compartment of blood. Mean peak plasma concentration of OLZ was 11 ng/ml, whereas that of radioactivity was 39 ng eq/ml. Mean plasma terminal elimination half-lives were 27 and 59 hr, respectively, for OLZ and total radioactivity. With the help of NMR and MS data, a major metabolite of OLZ in humans was characterized as a novel tertiary N-glucuronide in which the glucuronic acid moiety is attached to the nitrogen at position 10 of the benzodiazepine ring. Another N- glucuronide was detected in urine and identified as the quaternary N-linked 4'-N-glucuronide. Oxidative metabolism on the allylic methyl group resulted in 2-hydroxymethyl and 2-carboxylic acid derivatives of OLZ. The methyl piperazine moiety was also subject to oxidative attack, giving rise to the N-oxide and N-desmethyl metabolites. Other metabolites, including the N- desmethyl-2-carboxy derivative, resulted from metabolic reactions at both the 4' nitrogen and 2-methyl groups. The 10-N-glucuronide end OLZ were the two most abundant urinary components, accounting for ~13% and 7% of the dose, respectively. In fecal extracts, the only significant radioactive HPLC peaks were due to 10-N-glucuronide and OLZ representing, respectively, ~8% and 2% of the administered dose. Semiquantitative data obtained from plasma samples from subjects given [14C]OLZ suggest that the main circulating metabolite is 10-N-glucuronide. Thus, OLZ was extensively metabolized in humans via N-glucuronidation, allylic hydroxylation, N-oxidation, N- dealkylation and a combination thereof. The 10-N-glucuronidation pathway was the most important pathway both in terms of contribution to drug-related circulating species and as an excretory product in feces and urine.

AB - Disposition and biotransformation of the new antipsychotic agent olanzapine (OLZ) were studied in six male healthy volunteers after a single oral dose of 12.5 mg containing 100 μCi of [14C]OLZ. Biological fluids were analyzed for total radioactivity, the parent compound (GC/MS), and metabolites (electrospray LC/MB and LC/MS/MS). Mean radiocarbon recovery was ~87%, with 30% appearing in the faces and 57% excreted in the urine. Approximately half of the radiocarbon was excreted within 3 days, whereas >70% of the dose was recovered within 7 days of dosing. Circulating radioactivity was mostly restricted to the plasma compartment of blood. Mean peak plasma concentration of OLZ was 11 ng/ml, whereas that of radioactivity was 39 ng eq/ml. Mean plasma terminal elimination half-lives were 27 and 59 hr, respectively, for OLZ and total radioactivity. With the help of NMR and MS data, a major metabolite of OLZ in humans was characterized as a novel tertiary N-glucuronide in which the glucuronic acid moiety is attached to the nitrogen at position 10 of the benzodiazepine ring. Another N- glucuronide was detected in urine and identified as the quaternary N-linked 4'-N-glucuronide. Oxidative metabolism on the allylic methyl group resulted in 2-hydroxymethyl and 2-carboxylic acid derivatives of OLZ. The methyl piperazine moiety was also subject to oxidative attack, giving rise to the N-oxide and N-desmethyl metabolites. Other metabolites, including the N- desmethyl-2-carboxy derivative, resulted from metabolic reactions at both the 4' nitrogen and 2-methyl groups. The 10-N-glucuronide end OLZ were the two most abundant urinary components, accounting for ~13% and 7% of the dose, respectively. In fecal extracts, the only significant radioactive HPLC peaks were due to 10-N-glucuronide and OLZ representing, respectively, ~8% and 2% of the administered dose. Semiquantitative data obtained from plasma samples from subjects given [14C]OLZ suggest that the main circulating metabolite is 10-N-glucuronide. Thus, OLZ was extensively metabolized in humans via N-glucuronidation, allylic hydroxylation, N-oxidation, N- dealkylation and a combination thereof. The 10-N-glucuronidation pathway was the most important pathway both in terms of contribution to drug-related circulating species and as an excretory product in feces and urine.

UR - http://www.scopus.com/inward/record.url?scp=0031030609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031030609&partnerID=8YFLogxK

M3 - Article

C2 - 9010634

AN - SCOPUS:0031030609

VL - 25

SP - 81

EP - 93

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 1

ER -